Cardiome Reports First Quarter Results


    VANCOUVER, May 15 /CNW/ - Cardiome Pharma Corp. (NASDAQ:   CRME/TSX: COM)
today reported financial results for the first quarter ended March 31, 2009.
Amounts, unless specified otherwise, are expressed in Canadian dollars and in
accordance with Canadian Generally Accepted Accounting Principles (Canadian
GAAP). At close of business on March 31, 2009, the exchange rate was

    Results of Operations

    We recorded a net loss of $12.0 million ($0.19 per common share) for the
three months ended March 31, 2009 ("Q1-2009"), compared to a net loss of $22.2
million ($0.35 per common share) for the three months ended March 31, 2008
("Q1-2008"). The decrease in net loss for the current quarter was largely due
to decreased research and development expenditures related to vernakalant
(oral) and GED-aPC clinical activities.
    Revenue for Q1-2009 was $0.2 million, a decrease of $0.2 million from
$0.4 million in Q1-2008.
    Research and development expenditures were $7.7 million for Q1-2009
compared to $18.2 million for Q1-2008. The decrease of $10.5 million in
Q1-2009 was primarily due to the completion of the Phase 2b trial for
vernakalant (oral) in fiscal 2008. General and administration (G&A)
expenditures for both Q1-2009 and Q1-2008 were $4.1 million. Amortization for
Q1-2009 was $0.8 million compared to $1.0 million for Q1-2008. Interest and
other income for Q1-2009 was $0.03 million compared to $0.3 million in
Q1-2008. Foreign exchange gains remained consistent at $0.3 million in both
Q1-2009 and Q1-2008.
    Stock-based compensation, a non-cash item included in operating expenses,
decreased to $0.4 million for Q1-2009, as compared to $1.0 million for

    Liquidity and Outstanding Share Capital

    At March 31, 2009, the Company had cash and cash equivalents of $24.5
million. As of May 15, 2009, the Company had 63,766,296 common shares issued
and outstanding, 2,272,727 Series A preferred shares, and 4,806,062 common
shares issuable upon the exercise of outstanding stock options at a
weighted-average exercise price of $8.29 per share.

    Agreement with Merck & Co., Inc.

    Subsequent to quarter end, in April 2009 we announced a collaboration and
license agreement with Merck & Co., Inc. for the development and
commercialization of vernakalant. The agreement provides Merck with exclusive
global rights to vernakalant (oral), and provides exclusive rights outside of
the United States, Canada and Mexico to vernakalant (iv).
    Effectiveness of the collaboration agreement is subject to the expiration
or earlier termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act. Under terms of the agreement, on effectiveness of
the agreement Merck will pay Cardiome an initial upfront fee of US$60 million.
Further terms of the agreement are outlined in our press release dated April
8, 2009.

    Conference Call Notification

    In consideration of a Canadian statutory and market holiday on Monday,
May 18, 2009, Cardiome will hold its quarterly teleconference and webcast on
Tuesday, May 19, 2009 at 9:00am Eastern (6:00am Pacific). To access the
conference call, please dial 416-340-2217 or 866-696-5910 and reference
passcode 7124357. There will be a separate dial-in line for analysts on which
we will respond to questions at the end of the call. The webcast can be
accessed through Cardiome's website at
    Webcast and telephone replays of the conference call will be available
approximately two hours after the completion of the call through June 19,
2009. Please dial 416-695-5800 or 800-408-3053 and enter passcode 7312852
followed by the number sign to access the replay.

    About Cardiome Pharma Corp.

    Cardiome Pharma Corp. is a product-focused drug development company
dedicated to the advancement and commercialization of novel treatments for
disorders of the heart and circulatory system. Cardiome is traded on the
NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more
information, please visit our web site at

    Forward-Looking Statement Disclaimer

    Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 or forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including without
limitation statements containing the words "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect" and similar
expressions. Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements or information. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with the completion of clinical trials and
obtaining regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and uncertainties
that could cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any
future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties that:
we may not be able to successfully develop and obtain regulatory approval for
vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation
or any other current or future products in our targeted indications; our
future operating results are uncertain and likely to fluctuate; we may not be
able to raise additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we may not be
able to establish marketing and sales capabilities and the costs of launching
our products may be greater than anticipated; we rely on third parties for the
continued supply and manufacture of vernakalant (iv) and vernakalant (oral)
and we have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased competition
from pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Securities and Exchange Commission
available at and the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to
place undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent events or
circumstances, except as required by law.

For further information:

For further information: Peter K. Hofman, Senior Director, Investor
Relations, (604) 676-6993 or Toll Free: 1-800-330-9928, Email:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890